These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18501306)

  • 1. [The 20-core prostate biopsy protocol: a new gold standard?].
    Irani J
    Prog Urol; 2008 Apr; 18(4):251-2. PubMed ID: 18501306
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: The 20-core prostate biopsy protocol--a new gold standard?: V. Ravery, S. Dominique, X. Panhard, M. Toublanc, L. Boccon-Gibod and L. Boccon-Gibod. J Urol 2008; 179: 504-507.
    Serefoglu EC; Ozdemir AT; Balbay MD
    J Urol; 2008 Nov; 180(5):2256-7. PubMed ID: 18804806
    [No Abstract]   [Full Text] [Related]  

  • 3. Free PSA/total PSA ratio increases the detection rate of prostate cancer in twelve-core biopsy.
    Yokomizo Y; Miyoshi Y; Nakaigawa N; Makiyama K; Ogawa T; Yao M; Kubota Y; Uemura H
    Urol Int; 2009; 82(3):280-5. PubMed ID: 19440014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of free prostate-specific antigen measurement in prostate-specific antigen screening for prostate cancer.
    Johnson L
    Clin Prostate Cancer; 2002 Dec; 1(3):142-4. PubMed ID: 15046688
    [No Abstract]   [Full Text] [Related]  

  • 5. Fraction of positive cores in prostate needle biopsy is significantly predictive of pathological stage in radical prostatectomy.
    Brimo F; Vollmer RT; Bismar TA
    Histopathology; 2009 Feb; 54(3):374-5. PubMed ID: 19236514
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment.
    Gupta A; Lilja H
    Urology; 2011 Apr; 77(4):903-4; author reply 904. PubMed ID: 21477718
    [No Abstract]   [Full Text] [Related]  

  • 7. Intensifying the saturation biopsy technique for detecting prostate cancer after previous negative biopsies: a step in the wrong direction.
    Bott S; Langley S; Hindley R; Montgomery B
    BJU Int; 2009 Mar; 103(5):701. PubMed ID: 19226428
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting prostate cancer for focal destruction: can we find it?
    Taneja SS; Tareen B
    Cancer; 2008 Oct; 113(7):1500-1. PubMed ID: 18726950
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
    Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
    Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of prostate cancer: yes or no?].
    Van Cangh PJ
    Bull Mem Acad R Med Belg; 2006; 161(3-4):159-69. PubMed ID: 17172224
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
    Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
    J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing risk: does this patient have prostate cancer?
    Carter HB
    J Natl Cancer Inst; 2006 Apr; 98(8):506-7. PubMed ID: 16622114
    [No Abstract]   [Full Text] [Related]  

  • 13. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we accurately identify men with low risk prostate cancer?
    Neal DE
    J Urol; 2008 Oct; 180(4):1217-8. PubMed ID: 18707718
    [No Abstract]   [Full Text] [Related]  

  • 16. Predicting the risk of prostate cancer on biopsy.
    Ebell MH
    Am Fam Physician; 2005 Sep; 72(6):1091-2. PubMed ID: 16190507
    [No Abstract]   [Full Text] [Related]  

  • 17. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
    Thompson IM; Ankerst DP; Etzioni R; Wang T
    J Urol; 2008 Oct; 180(4):1219-22. PubMed ID: 18707707
    [No Abstract]   [Full Text] [Related]  

  • 18. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
    Shao Q; Song J; Zhou ZJ; Du LD
    Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do changes in a high serum prostate-specific antigen level and the free/total prostate-specific antigen ratio after antibiotic treatment rule out biopsy and the suspicion of cancer?
    Dirim A; Tekin MI; Koyluoglu E; Oguzulgen AI; Peskircioglu L; Ozkardes H
    Urol Int; 2009; 82(3):266-9. PubMed ID: 19440011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.